Singapore markets open in 4 hours 7 minutes
  • Straits Times Index

    3,173.82
    -0.09 (-0.00%)
     
  • S&P 500

    4,486.46
    +15.09 (+0.34%)
     
  • Dow

    35,258.61
    -36.15 (-0.10%)
     
  • Nasdaq

    15,021.81
    +124.47 (+0.84%)
     
  • BTC-USD

    61,141.50
    +1,536.65 (+2.58%)
     
  • CMC Crypto 200

    1,430.53
    -21.11 (-1.45%)
     
  • FTSE 100

    7,203.83
    -30.20 (-0.42%)
     
  • Gold

    1,764.90
    -3.40 (-0.19%)
     
  • Crude Oil

    82.24
    -0.04 (-0.05%)
     
  • 10-Yr Bond

    1.5840
    +0.0650 (+4.28%)
     
  • Nikkei

    29,025.46
    +474.56 (+1.66%)
     
  • Hang Seng

    25,409.75
    +78.75 (+0.31%)
     
  • FTSE Bursa Malaysia

    1,605.97
    +13.45 (+0.84%)
     
  • Jakarta Composite Index

    6,658.77
    +32.66 (+0.49%)
     
  • PSE Index

    7,219.81
    +36.70 (+0.51%)
     

Baudax Bio to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

MALVERN, Pa., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will participate in a virtual fireside chat at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Wednesday, September 22, 2021 at 1:15 p.m. ET.

A live webcast of the fireside chat will be available on the “Presentations” page within the investors section of the Baudax Bio website at https://www.baudaxbio.com/news-and-investors. A replay will be available on the Baudax Bio website for a period of 30 days following the event.

About Baudax Bio

Baudax Bio is a pharmaceutical company focused on commercializing and developing innovative products for acute care settings. ANJESO is the first and only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two novel neuromuscular blocking agents (NMBAs) and a proprietary chemical reversal agent specific to these NMBAs. For more information, please visit www.baudaxbio.com.

CONTACTS:

Investor Relations Contact:
Argot Partners
Sam Martin / Claudia Styslinger
(212) 600-1902
baudaxbio@argotpartners.com

Media Contact:
Argot Partners
David Rosen
(212) 600-1902
david.rosen@argotpartners.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting